Share on StockTwits

Salix Pharmaceuticals (NASDAQ:SLXP)’s share price reached a new 52-week high on Tuesday, AnalystRatings.NET reports. The company traded as high as $100.20 and last traded at $99.58, with a volume of 761,253 shares traded. The stock had previously closed at $98.56.

A number of research firms have recently commented on SLXP. Analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note to investors on Monday. They now have a $103.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Salix Pharmaceuticals to $115.00 in a research note to investors on Friday. Finally, analysts at Mizuho raised their price target on shares of Salix Pharmaceuticals from $101.00 to $127.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $88.63.

In other Salix Pharmaceuticals news, Director Alonzo Thomas D sold 12,050 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $91.83, for a total value of $1,106,551.50. Following the completion of the sale, the director now directly owns 97,974 shares in the company, valued at approximately $8,996,952. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Salix Pharmaceuticals has a 1-year low of $45.86 and a 1-year high of $99.24. The stock’s 50-day moving average is $88.62 and its 200-day moving average is $76.01. The company has a market cap of $6.293 billion and a P/E ratio of 58.56.

Salix Pharmaceuticals (NASDAQ:SLXP) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.89 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.86 by $0.03. The company had revenue of $238.20 million for the quarter, compared to the consensus estimate of $239.70 million. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 28.7% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $3.22 earnings per share for the current fiscal year.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.